FDA Wants New Warnings On Prostate Cancer Drugs

Law360, New York (October 20, 2010, 6:32 PM EDT) -- The U.S. Food and Drug Administration on Wednesday recommended new warning labels for certain prostate cancer drugs sold by Pfizer Inc., Bayer AG and others to inform consumers about the potential risk of heart disease and diabetes.

The FDA's Division of Drug Information urged manufacturers to include the warnings on gonadotropin-releasing hormone agonists — a class of drugs mostly used to treat prostate cancer — to alert patients and health care professionals of the drugs' potential side effects.

Patients who took GnRH agonists showed a small...
To view the full article, register now.